KalVista Pharmaceuticals (NASDAQ:KALV) Trading Up 7.1% - Should You Buy?

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) shares traded up 7.1% during mid-day trading on Monday . The company traded as high as $12.82 and last traded at $12.64. 305,442 shares changed hands during mid-day trading, a decline of 28% from the average session volume of 426,841 shares. The stock had previously closed at $11.80.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Jones Trading reaffirmed a "buy" rating and issued a $30.00 target price on shares of KalVista Pharmaceuticals in a report on Wednesday, March 26th. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 target price on shares of KalVista Pharmaceuticals in a report on Friday, March 14th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a report on Tuesday, April 8th. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus price target of $24.83.

KalVista Pharmaceuticals Trading Up 1.4%

The company has a market cap of $673.15 million, a price-to-earnings ratio of -3.72 and a beta of 0.05. The company has a fifty day moving average price of $11.97 and a two-hundred day moving average price of $10.54.

Insider Activity at KalVista Pharmaceuticals

In related news, CEO Benjamin L. Palleiko sold 6,669 shares of the business's stock in a transaction on Friday, March 7th. The stock was sold at an average price of $11.97, for a total value of $79,827.93. Following the sale, the chief executive officer now owns 287,811 shares of the company's stock, valued at $3,445,097.67. The trade was a 2.26% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Venrock Healthcare Capital Par acquired 25,000 shares of the business's stock in a transaction on Wednesday, April 9th. The stock was acquired at an average price of $9.42 per share, with a total value of $235,500.00. Following the transaction, the insider now owns 5,303,985 shares in the company, valued at approximately $49,963,538.70. The trade was a 0.47% increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 15,399 shares of company stock valued at $182,054 in the last 90 days. 10.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Several institutional investors have recently bought and sold shares of KALV. Aquatic Capital Management LLC bought a new position in KalVista Pharmaceuticals in the 4th quarter valued at $44,000. Earned Wealth Advisors LLC bought a new stake in shares of KalVista Pharmaceuticals during the first quarter worth $44,000. GAMMA Investing LLC raised its position in shares of KalVista Pharmaceuticals by 567.3% during the first quarter. GAMMA Investing LLC now owns 4,431 shares of the specialty pharmaceutical company's stock worth $51,000 after acquiring an additional 3,767 shares during the last quarter. CWM LLC raised its position in shares of KalVista Pharmaceuticals by 12,636.1% during the first quarter. CWM LLC now owns 4,585 shares of the specialty pharmaceutical company's stock worth $53,000 after acquiring an additional 4,549 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its position in shares of KalVista Pharmaceuticals by 666.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company's stock worth $54,000 after acquiring an additional 5,502 shares during the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).